Related Articles
Response to alectinib after one year of discontinuation of crizotinib in anaplastic lymphoma kinase-positive non-small-cell lung cancer: A case report
Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non‑small cell lung cancer (Review)
Activation of Src signaling mediates acquired resistance to ALK inhibition in lung cancer
Efficacy and survival outcomes of alectinib vs. crizotinib in ALK‑positive NSCLC patients with CNS metastases: A retrospective study
ALK inhibitors and advanced non-small cell lung cancer (Review)